FDA Brief

Warning letters Biologics

FDA warning letter to

Innate Healthcare Institute

High riskIssued Aug 15, 2025Posted Aug 26, 2025Center for Biologics Evaluation and Research (CBER)

FDA warned Arizona clinic Innate Healthcare Institute for selling unapproved umbilical cord stem cells marketed to treat autism.

What happened

FDA reviewed the company's website (last visited August 2025) and found it advertised "umbilical cord mesenchymal stem cells (UC-MSCs)" as a treatment for autism and a long list of other conditions. No inspection was reported; the finding came from the website review. FDA said the product is a drug and a biological product with no approved license, and that it does not qualify for the lighter HCT/P rules (HCT/P means human cells, tissues, or cellular products).

What FDA found

  1. The company markets its stem cell product to treat autism and many other diseases, which makes it a drug and biological product, but it has no approved license (BLA) to sell it.

    Section 351(a)(1) of the PHS Act, 42 U.S.C. § 262(a)(1); section 201(g)(1) of the FD&C Act, 21 U.S.C. § 321(g)(1)
  2. Processing the umbilical cord into an injectable form changes its original physical structure, so it counts as more than minimal manipulation and loses the lighter HCT/P status.

    21 CFR 1271.10(a)(1); 21 CFR 1271.3(f)(1)
  3. The product is not meant to do the same basic job in the patient as the cord does in the donor, because it is intended to treat autism rather than act as a conduit.

    21 CFR 1271.10(a)(2); 21 CFR 1271.3(c)
  4. The product does not carry adequate directions for use, so it is misbranded.

    Section 502(f)(1) of the FD&C Act, 21 U.S.C. § 352(f)(1); 21 CFR 201.5
  5. Holding misbranded product for sale after it has moved in interstate commerce is prohibited.

    Section 301(k) of the FD&C Act, 21 U.S.C. § 331(k)
  6. The company also markets exosomes, which FDA treats as drugs and biological products needing premarket review, and FDA pointed to its safety notice about serious harm in patients given exosome products.

    Section 201(g)(1) of the FD&C Act; section 351 of the PHS Act

What FDA wants

FDA tells the company to respond in writing within 15 working days describing the specific steps it has taken or will take, with documents showing the problems are fixed. If the company believes it is not breaking the law, it must send its reasoning and supporting information.

Who should pay attention

  • clinics that inject birth-tissue or "stem cell" products
  • companies marketing exosome products
  • suppliers and distributors of umbilical cord tissue products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk